Current plasma biomarkers include predictive models for diagnosing or grading steatosis (such as the fatty liver index) or staging fibrosis (such as the NAFLD fibrosis score), and other ones specific to NAFLD (such as the BARD and NAFLD fibrosis scores), even if some have been initially developed in a hepatitis C setting (AST/ALT ratio, APRI, FIB-4) [63]. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.